← Leaderboards
Elizabeth Ann Eklund
University Of Alabama At Birmingham
$14,527,585
Attributed
$14,527,585
Total exposure
15
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.4M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,527,585 · 12
VA$0 · 3
By mechanism
R01$12,518,454 · 9
T32$1,510,475 · 1
P30$397,856 · 1
R29$100,800 · 1
I01$0 · 3
Top collaborators
No co-investigators on record.
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- Josef T Prchal$8,723,783
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsMolecularPathway InteractionsBone MarrowMutationLeukemiaTherapeutic TargetMyeloproliferative DiseaseGenesGene ExpressionApoptosisMyeloid LeukemiaResponseTranscription FactorEventMediatingProteinsPreventTransplantationLeukemogenesisCytokineBone Marrow CellsHematopoiesisResistance
Grant awards (71)
In chronic myeloid leukemia, persistence of leukemia stem cells during tyrosine kinase inhibitor treatment is influenced by interaction with αβT cells$477,218
R01 · FY2025 · CA · contact PI
Molecular mechanisms of drug resistance and disease progression in acute myeloid leukemia.$0
I01 · FY2025 · VA · contact PI
Hematologic Malignancies (HM) Research Program$60,775
P30 · FY2024 · CA · contact PI
Molecular mechanisms of drug resistance and disease progression in acute myeloid leukemia.$0
I01 · FY2024 · VA · contact PI
Identifying molecular markers that predict relapse after therapy discontinuation in chronic myeloid leukemia.$0
I01 · FY2024 · VA · contact PI
Hematologic Malignancies (HM) Research Program$60,775
P30 · FY2023 · CA · contact PI
Molecular mechanisms of drug resistance and disease progression in acute myeloid leukemia.$0
I01 · FY2023 · VA · contact PI
Molecular mechanisms for bone marrow failure and clonal progression during the innate immune response in Fanconi Anemia$355,665
R01 · FY2022 · DK · contact PI
Hematologic Malignancies (HM) Research Program$50,261
P30 · FY2022 · CA · contact PI
Molecular mechanisms of drug resistance and disease progression in acute myeloid leukemia$0
I01 · FY2022 · VA · contact PI
Identifying molecular markers that predict relapse after therapy discontinuation inchronic myeloid leukemia.$0
I01 · FY2022 · VA · contact PI
Molecular mechanisms for bone marrow failure and clonal progression during the innate immune response in Fanconi Anemia$355,637
R01 · FY2021 · DK · contact PI
Hematologic Malignancies (HM) Research Program$50,261
P30 · FY2021 · CA · contact PI
Identifying molecular markers that predict relapse after therapy discontinuation inchronic myeloid leukemia.$0
I01 · FY2021 · VA · contact PI
Molecular mechanisms of drug resistance and disease progression in acute myeloid leukemia$0
I01 · FY2021 · VA · contact PI
Identifying molecular markers that predict relapse after therapy discontinuation inchronic myeloid leukemia.$0
I01 · FY2021 · VA · contact PI
Molecular mechanisms for bone marrow failure and clonal progression during the innate immune response in Fanconi Anemia$356,225
R01 · FY2020 · DK · contact PI
Hematologic Malignancies (HM) Research Program$50,261
P30 · FY2020 · CA · contact PI
Molecular mechanisms of drug resistance and disease progression in acute myeloid leukemia$0
I01 · FY2020 · VA · contact PI
Molecular mechanisms for bone marrow failure and clonal progression during the innate immune response in Fanconi Anemia$368,096
R01 · FY2019 · DK · contact PI
Triad1 regulates myelopoiesis and functions as a leukemia suppressor$342,815
R01 · FY2019 · CA · contact PI
Hematologic Malignancies (HM) Research Program$50,261
P30 · FY2019 · CA · contact PI
Identifying molecular markers that predict relapse after therapy discontinuation inchronic myeloid leukemia.$0
I01 · FY2019 · VA · contact PI
Molecular mechanisms of drug resistance and disease progression in acute myeloid leukemia$0
I01 · FY2019 · VA · contact PI
Training Program in Oncogenesis and Developmental Biology$366,692
T32 · FY2018 · CA · contact PI
Triad1 regulates myelopoiesis and functions as a leukemia suppressor$353,419
R01 · FY2018 · CA · contact PI
Hematologic Malignancies (HM) Research Program$51,258
P30 · FY2018 · CA · contact PI
Hematologic Malignancies (HM) Research Program$8,620
P30 · FY2018 · CA · contact PI
Hematologic Malignancies (HM) Research Program$8,488
P30 · FY2018 · CA · contact PI
Hematologic Malignancies (HM) Research Program$6,896
P30 · FY2018 · CA · contact PI
Triad1 regulates myelopoiesis and functions as a leukemia suppressor$353,419
R01 · FY2017 · CA · contact PI
Training Program in Oncogenesis and Developmental Biology$339,375
T32 · FY2017 · CA · contact PI
The role of emergency granulopoiesis in the pathogenesis of Fanconi Anemia$336,038
R01 · FY2017 · DK · contact PI
The role of ICSBP in the pathogenesis of chronic myeloid leukemia$320,588
R01 · FY2017 · CA · contact PI
Training Program in Oncogenesis and Developmental Biology$4,305
T32 · FY2017 · CA · contact PI
Triad1 regulates myelopoiesis and functions as a leukemia suppressor$353,419
R01 · FY2016 · CA · contact PI
The role of emergency granulopoiesis in the pathogenesis of Fanconi Anemia$336,038
R01 · FY2016 · DK · contact PI
The role of ICSBP in the pathogenesis of chronic myeloid leukemia$320,588
R01 · FY2016 · CA · contact PI
Training Program in Oncogenesis and Developmental Biology$319,746
T32 · FY2016 · CA · contact PI
Molecular Mechanisms of Disease Progression in Myeloid Malignancy$0
I01 · FY2016 · VA · contact PI
Triad1 regulates myelopoiesis and functions as a leukemia suppressor$353,419
R01 · FY2015 · CA · contact PI
The role of emergency granulopoiesis in the pathogenesis of Fanconi Anemia$336,038
R01 · FY2015 · DK · contact PI
The role of ICSBP in the pathogenesis of chronic myeloid leukemia$320,588
R01 · FY2015 · CA · contact PI
Training Program in Oncogenesis and Developmental Biology$318,220
T32 · FY2015 · CA · contact PI
Molecular Mechanisms of Disease Progression in Myeloid Malignancy$0
I01 · FY2015 · VA · contact PI
The role of emergency granulopoiesis in the pathogenesis of Fanconi Anemia$336,038
R01 · FY2014 · DK · contact PI
The role of ICSBP in the pathogenesis of chronic myeloid leukemia$310,970
R01 · FY2014 · CA · contact PI
Training Program in Oncogenesis and Developmental Biology$162,137
T32 · FY2014 · CA · contact PI
Molecular Mechanisms of Disease Progression in Myeloid Malignancy$0
I01 · FY2014 · VA · contact PI
The role of ICSBP in the pathogenesis of chronic myeloid leukemia$320,588
R01 · FY2013 · CA · contact PI
Molecular Mechanisms of Disease Progression in Myeloid Malignancy$0
I01 · FY2013 · VA · contact PI
ICSBP Function During Myeloid Differentiation$377,500
R01 · FY2011 · HL · contact PI
HoxA10 Function During Myeloid Differentiation$377,500
R01 · FY2011 · HL · contact PI
HoxA10 Function During Myeloid Differentiation$377,500
R01 · FY2010 · HL · contact PI
ICSBP Function During Myeloid Differentiation$377,500
R01 · FY2010 · HL · contact PI
ICSBP Function During Myeloid Differentiation$377,500
R01 · FY2009 · HL · contact PI
HoxA10 Function During Myeloid Differentiation$377,500
R01 · FY2009 · HL · contact PI
ICSBP Function During Myeloid Differentiation$377,500
R01 · FY2008 · HL · contact PI
HoxA10 Function During Myeloid Differentiation$377,500
R01 · FY2008 · HL · contact PI
HoxA10 Function During Myeloid Differentiation$377,500
R01 · FY2007 · HL · contact PI
ICSBP Function During Myeloid Differentiation$290,383
R01 · FY2006 · CA · contact PI
HoxA10 Function During Myeloid Differentiation$258,382
R01 · FY2006 · CA · contact PI
ICSBP Function During Myeloid Differentiation$297,371
R01 · FY2005 · CA
HoxA10 Function During Myeloid Differentiation$264,600
R01 · FY2005 · CA
ICSBP Function During Myeloid Differentiation$297,371
R01 · FY2004 · CA
HoxA10 Function During Myeloid Differentiation$264,600
R01 · FY2004 · CA
ICSBP Function During Myeloid Differentiation$297,371
R01 · FY2003 · CA
HoxA10 Function During Myeloid Differentiation$264,600
R01 · FY2003 · CA
HoxA10 Function During Myeloid Differentiation$279,470
R01 · FY2002 · CA
GP91-PHOX TRANSCRIPTION FACTORS AND HEMATOPOIESIS$68,235
R29 · FY2000 · HL
GP91-PHOX TRANSCRIPTION FACTORS AND HEMATOPOIESIS$32,565
R29 · FY2000 · HL